Abstracts

Comparison of Adherence Measures in a Clinical Trial of Preexposure Prophylaxis

Background: No gold standard exists for adherence measurement. Self-report is commonly used but it is subjective. Objective measures are more costly and difficult to implement. Research is limited on the performance of these measures for pre-exposure prophylaxis (PrEP) against HIV infection. Methods: The Partners PrEP Ancillary Adherence Study collected the following adherence measures in 1,147…

Self-Reported Recent PrEP Use Has Strong Relation to Drug Detection in iPrEx OLE

Background: Gross inaccuracies in participant-reported adherence has dampened or eliminated confidence in self-report as a method to characterize PrEP use. Sophisticated measurement strategies available in clinical trials, however, are unlikely candidates for adoption in clinical practice, contributing to concerns about PrEP roll-out. Self-report of self-selected open-label PrEP use has not been characterized to date and…

HPTN 067/ADAPT Cape Town: A Comparison of Daily and Nondaily PrEP Dosing in African Women

Background: HIV pre-exposure chemoprophylaxis (PrEP) is becoming a standard of prevention care in many countries; however concerns about costs and side effects can limit uptake. The HPTN 067 ADAPT trial, a Phase II, randomized, open-label clinical trial of oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) PrEP, included a cohort of South African women in Cape Town. The…

Intimate Partner Violence Is Associated With Low PrEP Adherence in African Women

Background: Intimate partner violence (IPV) has been associated with increased risk for HIV acquisition. Women who experience IPV are thus a potential target population for pre-exposure prophylaxis (PrEP) to prevent HIV infection. However, high adherence levels are required for PrEP efficacy, and IPV exposure is associated with lower adherence to other medication regimens. Studies have…

Reversibility of Kidney Function Decline in HIV-1–Uninfected Men and Women Using Preexposure Prophylaxis

Background: Tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP) use is associated with a small but statistically significant decline in estimated glomerular filtration rate (eGFR). We investigated the occurrence and reversibility of eGFR decline among HIV-1 uninfected adults discontinuing PrEP. Methods: Data are from the Partners PrEP Study, a trial of daily oral tenofovir disoproxil fumarate (TDF)…

Minor Drug-Resistant Variants Infrequently Detected in Seroconverters From MTN 003 (VOICE)

Background: Minor (low frequency) drug-resistant variants selected by antiretroviral (ARV)-based prevention could negatively impact response to future antiretroviral therapy. We previously reported (Marrazzo et al., NEJM 2014) that acquired resistance to ARV-based products in the MTN 003 (VOICE) study was rarely detected by standard population based genotype analysis (1/212 participants receiving active product), with no…

PrEP-Selected Drug Resistance Fades by Six Months Following Drug Cessation

Background: Pre-exposure prophylaxis (PrEP) significantly reduces HIV-1 transmission. However, selection for drug resistance may occur when PrEP is initiated during unrecognized acute infection or in breakthrough infections during periods of low PrEP adherence. In these cases it remains unclear how long resistance persists after discontinuation of PrEP. Methods: The Partners PrEP Study was a randomized…

Randomized Controlled Trial on ART Outcomes in Tenofovir Gel Trial Seroconvertors

Background: Prior to promoting tenofovir gel for HIV prevention in women, it is important to know whether tenofovir gel users who acquire HIV infection can be treated with tenofovir containing antiretroviral treatment (ART) with good clinical outcomes. The CAPRISA009 randomised clinical trial assessed ART outcomes in women who acquired HIV during tenofovir gel trials. Methods:…

Frequent Dapivirine Cross-Resistance of HIV from 1st-line ART Failures in S. Africa

Background: Two Phase III studies (IPM Ring Study and MTN ASPIRE) are currently evaluating whether monthly use of a vaginal ring containing dapivirine (DPV) prevents HIV infection in women. The rise of transmitted EFV- and NVP-resistant virus could reduce the protective efficacy of DPV. This study investigated DPV cross-resistance among recombinant subtype C viruses derived…